RxDoctor Payments Data

Kenneth Lee, DO

Family Medicine · Ocala, FLNPI 1023195112

Payments from drug & device makers

$11,230in general payments, 2019–2025

Across 25 payments — averaging $449.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$9K
  • Johnson & Johnson$1K
  • Amgen$381
  • Stryker$253
  • Ironwood Pharmaceuticals, Inc$193
  • AbbVie$99
  • plus $209 from 5 others

What the payments were for

  • Food & beverage$2,16619%
  • Gifts$9,06481%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Tosoh Bioscience, Inc.2$9,064
Johnson & Johnson9$1,030
Amgen3$381
Stryker2$253
Ironwood Pharmaceuticals, Inc2$193
AbbVie1$99
Otsuka America Pharmaceutical, Inc.1$97
GSK2$35
Motiva USA, LLC1$29
Fisher Scientific Company L.L.C.1$27
Pfizer1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,230 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$689,992
Medicare patients
649
Services billed
27,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$67,670
JardianceEmpagliflozin54$65,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$33,005
JanuviaSitagliptin Phosphate27$21,522
MounjaroTirzepatide19$19,603
Breo ElliptaFluticasone/Vilanterol15$15,630
ShingrixVaricella-Zoster Ge/As01b/Pf60$13,531
OzempicSemaglutide11$12,945
JanumetSitagliptin Phos/Metformin Hcl13$12,508
MyrbetriqMirabegron14$10,590
Levothyroxine Sodium494$5,500
Atorvastatin Calcium485$5,235
Potassium Chloride112$5,145
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$4,379
Atovaquone12$4,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$20$69,02266 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$35$62,16596 claims
AbbVieSynthroid$99$2,37771 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →